{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:51:06Z","timestamp":1792511466234,"version":"4.5.0"},"reference-count":99,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2017,6,4]],"date-time":"2017-06-04T00:00:00Z","timestamp":1496534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>The management of chronic myeloid leukemia with BCR-ABL1 tyrosine kinase inhibitors has evolved chronic myeloid leukemia into a chronic, manageable disease. A patient-centered approach is important for the appropriate management of chronic myeloid leukemia and optimization of long-term treatment outcomes. The pharmacist plays a key role in treatment selection, monitoring drug\u2013drug interactions, identification and management of adverse events, and educating patients on adherence. The combination of tyrosine kinase inhibitors with unique safety profiles and individual patients with unique medical histories can make managing treatment difficult. This review will provide up-to-date information regarding tyrosine kinase inhibitor-based treatment of patients with chronic myeloid leukemia. Management strategies for adverse events and considerations for drug\u2013drug interactions will not only vary among patients but also across tyrosine kinase inhibitors. Drug\u2013drug interactions can be mild to severe. In instances where co-administration of concomitant medications cannot be avoided, it is critical to understand how drug levels are impacted and how subsequent dose modifications ensure therapeutic drug levels are maintained. An important component of patient-centered management of chronic myeloid leukemia also includes educating patients on the significance of early and regular monitoring of therapeutic milestones, emphasizing the importance of adhering to treatment in achieving these targets, and appropriately modifying treatment if these clinical goals are not being met. Overall, staying apprised of current research, utilizing the close pharmacist\u2013patient relationship, and having regular interactions with patients, will help achieve successful long-term treatment of chronic myeloid leukemia in the age of BCR-ABL1 tyrosine kinase inhibitors.<\/jats:p>","DOI":"10.1177\/1078155217710553","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T02:40:16Z","timestamp":1496630416000},"page":"433-452","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":43,"title":["BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia"],"prefix":"10.1177","volume":"24","author":[{"given":"Sandra","family":"Cuellar","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vozniak","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital of the University of Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Rhodes","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Louisville Hospital, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Forcello","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, Smilow Cancer Hospital at Yale New Haven, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Olszta","sequence":"additional","affiliation":[{"name":"Joliet Oncology & Hematology Associates Ltd, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,6,4]]},"reference":[{"key":"bibr1-1078155217710553","volume-title":"Gleevec\u00ae (imatinib mesylate) package insert","author":"Novartis","year":"2016"},{"key":"bibr2-1078155217710553","volume-title":"Sprycel\u00ae (dasatinib) package insert","author":"Bristol-Myers Squibb","year":"2015"},{"key":"bibr3-1078155217710553","volume-title":"Tasigna\u00ae (nilotinib) package insert","author":"Novartis","year":"2015"},{"key":"bibr4-1078155217710553","volume-title":"Bosulif\u00ae (bosutinib) package insert","author":"Pfizer","year":"2016"},{"key":"bibr5-1078155217710553","volume-title":"Iclusig\u00ae (ponatinib) package insert","author":"ARIAD","year":"2016"},{"key":"bibr6-1078155217710553","doi-asserted-by":"publisher","DOI":"10.2165\/11593320-000000000-00000"},{"key":"bibr7-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009333854"},{"key":"bibr8-1078155217710553","first-page":"85","volume":"5","author":"Wang X","year":"2013","journal-title":"Clin Pharmacol"},{"key":"bibr9-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-380774"},{"key":"bibr10-1078155217710553","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Chronic Myelogenous Leukemia (V.1.2017). \u00a9 National Comprehensive Cancer Network, Inc 2015\u00ae. All rights reserved, see NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK\u00ae, NCCN\u00ae, NCCN GUIDELINES\u00ae, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc (accessed 17 March 2017)."},{"key":"bibr11-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"bibr12-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"bibr13-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"bibr14-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"bibr15-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"bibr16-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0155"},{"key":"bibr17-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140665"},{"key":"bibr18-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/637059"},{"key":"bibr19-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"bibr20-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"bibr21-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"bibr22-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85"},{"key":"bibr23-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348110"},{"key":"bibr24-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"bibr25-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403158"},{"key":"bibr26-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166694"},{"key":"bibr27-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"bibr28-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"bibr29-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"bibr30-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030513"},{"key":"bibr31-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"bibr32-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423"},{"key":"bibr33-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds228"},{"key":"bibr34-1078155217710553","unstructured":"National Comprehensive Cancer Network. Tests and treatment responses in chronic phase CML, http:\/\/education.nccn.org\/sites\/education.nccn.org\/files\/HEM-N-0333-0415%20CML%20Pt%20Vignette%20Tool.pdf (accessed 14 March 2016)."},{"key":"bibr35-1078155217710553","unstructured":"Leukemia and Lymphoma Society. The CML guide, information for patients and caregivers, chronic myeloid leukemia, https:\/\/www.lls.org\/sites\/default\/files\/file_assets\/cmlguide.pdf (2014, accessed 30 March 2016)."},{"key":"bibr36-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1177\/1947601912462126"},{"key":"bibr37-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.08.004"},{"key":"bibr38-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"bibr39-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029828"},{"key":"bibr40-1078155217710553","unstructured":"Novartis.\n                      Tasigna\u00ae (nilotinib) [European Medicines Agency product information]\n                      . East Hanover, NJ: Novartis."},{"key":"bibr41-1078155217710553","doi-asserted-by":"crossref","unstructured":"American Cancer Society. Chronic myeloid leukemia, https:\/\/www.cancer.org\/cancer\/chronic-myeloid-leukemia.html (2017, accessed 17 May 2017).","DOI":"10.1016\/j.clml.2017.08.008"},{"key":"bibr42-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt266"},{"key":"bibr43-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.7550"},{"key":"bibr44-1078155217710553","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Older Adult Oncology (V.1.2017). \u00a9 National Comprehensive Cancer Network, Inc 2015\u00ae. All rights reserved, see NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK\u00ae, NCCN\u00ae, NCCN GUIDELINES\u00ae, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc (accessed 5 January 2017)."},{"key":"bibr45-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.39.1.1"},{"key":"bibr46-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294330"},{"key":"bibr47-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1177\/2042098612454283"},{"key":"bibr48-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"bibr49-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-617993"},{"key":"bibr50-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.09.008"},{"key":"bibr51-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29587"},{"key":"bibr52-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24186"},{"key":"bibr53-1078155217710553","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.028"},{"key":"bibr54-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-378919"},{"key":"bibr55-1078155217710553","unstructured":"US National Institutes of Health. ClinicalTrials.gov. Studies showing remission in CML, https:\/\/clinicaltrials.gov\/ct2\/results?term=remission&recr=&type=&rslt=&age_v=&gndr=&cond=CML&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&rcv_s=&rcv_e=&lup_s=&lup_e= (accessed 18 October 2016)."},{"key":"bibr56-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"bibr57-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"bibr58-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22019"},{"key":"bibr59-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"bibr60-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.06.006"},{"key":"bibr61-1078155217710553","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S70712"},{"key":"bibr62-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1159\/000444626"},{"key":"bibr63-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802174769"},{"key":"bibr64-1078155217710553","unstructured":"Liles DK, Lea CS, Moore TN, et\u00a0al. Barriers to adherence in hematologic malignancies in a rural regional hospital network. Presented at:\n                      American Society of Clinical Oncology Annual Meeting\n                      , Chicago, IL, 2\u20136 June 2016."},{"key":"bibr65-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-167"},{"key":"bibr66-1078155217710553","doi-asserted-by":"crossref","unstructured":"Degli-Esposti L, Saragoni S, Buda S, et\u00a0al. Medication adherence in patients with chronic myeloid leukemia using tyrosine-kinase inhibitors: a retrospective analysis. Presented at:\n                      American Society of Hematology Annual Meeting\n                      , San Francisco, CA, 6\u20139 December 2014.","DOI":"10.1182\/blood.V124.21.1808.1808"},{"key":"bibr67-1078155217710553","first-page":"1006","volume":"20","author":"Trivedi D","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr68-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903396469"},{"key":"bibr69-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2011.000316"},{"key":"bibr70-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214559114"},{"key":"bibr71-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215608523"},{"key":"bibr72-1078155217710553","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0127"},{"key":"bibr73-1078155217710553","first-page":"85","volume":"5","author":"Wang X","year":"2013","journal-title":"Clin Pharmacol"},{"key":"bibr74-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329"},{"key":"bibr75-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07108.x"},{"key":"bibr76-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.3432.3432"},{"key":"bibr77-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24155"},{"key":"bibr78-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2318-y"},{"key":"bibr79-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020461"},{"key":"bibr80-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/52.4.417"},{"key":"bibr81-1078155217710553","first-page":"1022","volume":"2","author":"Kimura S","year":"2014","journal-title":"J Hematol Transf"},{"key":"bibr82-1078155217710553","unstructured":"The National CML Society. Resources: assistance programs, http:\/\/www.nationalcmlsociety.org\/resources\/assistance-programs (July 2015, accessed 19 October 2016)."},{"key":"bibr83-1078155217710553","unstructured":"Mahon FX, Richter J, Guilhot J, et\u00a0al. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: Results of the Euro-Ski trial. Presented at:\n                      American Society of Hematology Annual Meeting\n                      , San Diego, CA, 3\u20136 December 2016."},{"key":"bibr84-1078155217710553","unstructured":"US National Institutes of Health. ClinicalTrials.gov. The life after stopping tyrosine kinase inhibitors study (The LAST study), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02269267?term=NCT02269267&rank=1 (accessed 18 January 2017)."},{"key":"bibr85-1078155217710553","doi-asserted-by":"crossref","unstructured":"Clark RE, Polydoros F, Apperley JF, et\u00a0al. Chronic myeloid leukaemia patients with stable molecular responses (at least MR3) may safely decrease the dose of their tyrosine kinase inhibitor: Data from the British Destiny study. Presented at:\n                      American Society of Hematology Annual Meeting\n                      , San Diego, CA, 3\u20136 December 2016.","DOI":"10.1182\/blood.V128.22.938.938"},{"key":"bibr86-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742205"},{"key":"bibr87-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00196-9"},{"key":"bibr88-1078155217710553","unstructured":"Shah NP, Paquette R, Muller MC, et\u00a0al. Treatment-free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML-CP) and in stable deep molecular response (DMR) to dasatinib \u2013 the Dasfree study. Presented at:\n                      American Society of Hematology Annual Meeting\n                      , San Diego, CA, 3\u20136 December 2016."},{"key":"bibr89-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1922.1922"},{"key":"bibr90-1078155217710553","unstructured":"UMIN Clinical Trials Registry. UMIN.ac.jp. Dasatinib treatment discontinuation study implementation plan for initial chronic phase chronic myelogenous leukemia with 1 year complete molecular genetic effect, https:\/\/translate.google.com\/translate?hl=en&sl=ja&u=https:\/\/upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi%3Ffunction%3Dbrows%26action%3Dbrows%26type%3Dsummary%26recptno%3DR000012999%26language%3DJ&prev=search (2013, accessed 22 March 2017)."},{"key":"bibr91-1078155217710553","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.V128.22.791.791","volume":"128","author":"Kumagai T","year":"2016","journal-title":"Blood"},{"key":"bibr92-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.345.345"},{"key":"bibr93-1078155217710553","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"bibr94-1078155217710553","unstructured":"Hochhaus A, Masszi T, Giles FJ, et\u00a0al. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study. Presented at:\n                      American Society of Clinical Oncology Annual Meeting\n                      , Chicago, IL, 3\u20137 June 2016."},{"key":"bibr95-1078155217710553","doi-asserted-by":"crossref","unstructured":"Ritchie EK, Catchatourian R, Klisovic RB, et\u00a0al. ENESTgoal treatment-free remission study: Updated preliminary results and digital polymerase chain reaction analysis in patients with chronic myeloid leukemia in chronic phase who switched from imatinib to nilotinib. Presented at:\n                      American Society of Hematology Annual Meeting\n                      , San Diego, CA, 3\u20136 December 2016.","DOI":"10.1182\/blood.V128.22.3090.3090"},{"key":"bibr96-1078155217710553","doi-asserted-by":"crossref","unstructured":"Rea D, Rosti G, Cross NCP, et\u00a0al. ENESTPath: A phase 3 study to assess the effect of nilotinib treatment duration on treatment-free remission (TFR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with imatinib: 24-month analysis of the first 300 patients in the induction\/consolidation phase. Presented at:\n                      American Society of Hematology Annual Meeting\n                      , San Diego, CA, 3\u20136 December 2016.","DOI":"10.1182\/blood.V128.22.3094.3094"},{"key":"bibr97-1078155217710553","unstructured":"Mahon FX, Boquimpani C, Takahashi N, et\u00a0al. Patient-reported quality of life before and after stopping treatment in the ENESTop trial of treatment-free remission for patients with chronic myeloid leukemia in chronic phase. Presented at:\n                      American Society of Hematology Annual Meeting\n                      , San Diego, CA, 3\u20136 December 2016."},{"key":"bibr98-1078155217710553","doi-asserted-by":"crossref","unstructured":"Kadowaki N, Kawaguchi T, Kuroda J, et\u00a0al. Discontinuation of nilotinib in patients with chronic myeloid leukemia who have maintained deep molecular responses for at least 2 years: A multicenter phase 2 stop nilotinib (Nilst) trial. Presented at:\n                      American Society of Hematology Annual Meeting\n                      , San Diego, CA, 3\u20136 December 2016.","DOI":"10.1182\/blood.V128.22.790.790"},{"key":"bibr99-1078155217710553","doi-asserted-by":"crossref","unstructured":"Takahashi N, Nakaseko C, Nishiwaki K, et\u00a0al. Two-year consolidation by nilotinib is associated with successful treatment free remission in chronic myeloid leukemia with MR: Subgroup analysis from STAT2 trial in Japan. Presented at\n                      American society of hematology annual meeting\n                      , San Diego, CA, 3\u20136 December 2016.","DOI":"10.1182\/blood.V128.22.1889.1889"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217710553","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217710553","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217710553","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:23Z","timestamp":1777688243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217710553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,4]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.1177\/1078155217710553"],"URL":"https:\/\/doi.org\/10.1177\/1078155217710553","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,4]]}}}